Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.
Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.
Brain tumors are the largest group of solid tumors and the leading cause of cancer-related deaths in childhood 1 . The most devastating of these is DIPG, which is almost universally fatal 2, 3 . Despite collaborative efforts to improve treatments, survival has remained static over decades, and DIPGs are now the main cause of brain tumor-related death in children. Diagnosis of DIPG is based on a combination of clinical and radiological findings; a tissue biopsy is rarely acquired. Radiation is the mainstay of therapy but offers only symptom control, and, so far, chemotherapy has shown no benefit 4 . A potential contributor to the failure of DIPG clinical trials is the use of agents targeting the genetic alterations of adult glioblastomas (GBMs) 5 . A number of recent studies have reported differences at both the copy number and expression levels that distinguish pediatric DIPGs from both their adult and pediatric supratentorial GBM counterparts [6] [7] [8] [9] , indicating that they may be separate biological entities requiring their own therapeutic strategies. Recent identification of frequent histone H3 gene mutations (encoding p.Lys27Met) in DIPGs has suggested that both genetic and epigenetic mechanisms may be important drivers of these tumors [10] [11] [12] . However, the complete genetic and epigenetic landscapes of DIPG and the functional role that histone modifications may have in DIPG remain unknown. These data are critical for the development of better therapies for affected children.
We integrated deep sequencing analysis of 36 tumor-normal pairs (20 whole-genome sequencing (Illumina HiSeq 2000) and 16 wholeexome sequencing (Applied Biosystems SOLiD 5500xl)) with comprehensive methylation ( Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations l e t t e r s sample pairs using Fluidigm Array Ion Torrent chip sequencing (Supplementary Table 3 ). Further, for key SNVs, we also tested a validation cohort of an additional 25 tumors. This analysis shows that, although previously considered to be one disease, DIPG represents three distinct subgroups with different methylation, expression, copy number alteration (CNA) and mutational profiles.
Unsupervised subgrouping of DIPG cases on the basis of CpG island methylation (Online Methods) resulted in three distinct subgroups; 'MYCN' , 'silent' and 'H3-K27M' (Fig. 1a) . This subgrouping was supported by multiple analyses, including principal-components analysis (Fig. 1b) , non-negative matrix factorization (Fig. 1c) and consensus clustering (Fig. 1d) . Subgroup-specific differences were supported by the integration of mutation, structural, expression and clinical data (Fig. 2) . The identification of DIPG subgroups will have key implications for the design of appropriate therapy for these tumors.
The MYCN subgroup had no recurrent mutations but was instead characterized by hypermethylation, high-grade histology and chromothripsis on chromosome 2p leading to recurrent high-level amplification of MYCN and ID2 ( Table 1 and Supplementary Figs. 1-3) . Tumors in this group overexpressed MYCN by 4-fold and 8-fold and ID2 by 2.5-fold and 5-fold relative to the H3-K27M and silent groups, respectively. The top most overexpressed genes in the MYCN group included FAP, HRSP12 and DYX2. Therapies aimed at targeting altered histone modifications would not be effective in this subgroup. Rather, children with this subtype of DIPG will potentially benefit from therapies targeting MYCN or possibly ID2. Tumors in the silent subgroup had silent genomes on the basis of both wholegenome sequencing, structural and SNP6.0 copy number analysis and had a lower mutation rate than tumors in the other two subgroups (median of 0.11 mutations per megabase (range of 0.02-0.19) in the silent cohort compared to 0.99 mutations per megabase (range of 0. [19] [20] [21] [22] [23] [24] in the other two groups; P = 0.05 (Supplementary Table 4) ). All DIPGs with low-grade astrocytoma (LGA) histology were from this group, although, interestingly, there was no difference in overall survival in comparison with the other subgroups. Affected individuals in this group were diagnosed at a significantly younger age (4.81 ± 1.64 years for the children from the silent group versus 6.89 ± 2.62 years for those not in the silent group; P = 0.04). The p.Lys27Met histone H3 alteration was present in 44% of tumors (p.Lys27Met histone H3.3 in 33% and p.Lys27Met histone H3.1 in 11%), but there were no recurrent copy number changes as observed in the MYCN and H3-K27M subgroups. At the expression level, the silent subgroup showed overexpression of WNT pathway genes (Supplementary Table 5) , as well as MDM2, MSMP and ADAM33, compared with the other two subgroups (Table 1) . Notably, DIPGs in neither the MYCN nor the silent subgroup had receptor tyrosine kinase gene amplification, suggesting that the group of inhibitors targeting these kinases will be less effective in patients with these DIPG subtypes.
H3-K27M subgroup DIPGs were highly mutated in either histone H3.3 (H3F3A) or H3.1 (HIST1H3B and HIST1H3C). This group had highly unstable genomes (segmentation analysis of SNP6.0 data; 497 CNAs per genome versus 300 CNAs per genome in the silent group; P = 0.04). Alternative lengthening of telomeres (ALT; detected by telomere restriction fragment assay 13 , the presence of C-circles 14 and/or telomere length from whole-genome sequencing data) is exclusively associated with the H3-K27M subgroup; only two of the tumors in this subgroup harbored ATRX mutations. ALT-positive cases were significantly older at the time of diagnosis (P < 0.001; Supplementary  Fig. 4) . Similarly, PVT1, MYC and PDGFRA gains or amplifications (Fig. 2a) and structural variants (Supplementary Fig. 5 ) were exclusive to this group. TP53 mutations were enriched in this group (67.9% versus 33.3% in other groups; P = 0.007). Given the complexity and D29  D52  D09  D18  D26  D63   H3-K27M   D19  D62  D60  D06  D57  D28  D24  D27  D25  D08  D30  D67  D58  D64  D78  D05  D07  D04  D56  D03 npg l e t t e r s heterogeneity of genetic changes for the H3-K27M subgroup, if therapies targeting the histone mutations become available, this subgroup would likely require multimodal therapies.
Certain mutations and structural variants were significantly more likely to co-occur-specifically, mutation encoding p.Lys27Met in histone H3.3 and PDGFRA amplifications (odds ratio (OR) = 8.0, P = 0.0127) and mutation encoding p.Lys27Met in histone H3.1 and ACVR1 mutations (OR = 15.8, P = 0.0004) (Fig. 2b) . Conversely, MYCN amplifications were statistically less likely to occur if a p.Lys27Met histone H3 alteration was present (OR = 0.019, P = 0.0103; Fig. 2b ). Affected individuals carrying p.Lys27Met alterations in histone H3.3 were more likely to have GBM histology (OR = 5.3, P = 0.0035), whereas p.Lys27Met alterations in histone H3.1 were more likely to occur in cases with anaplastic astrocytoma histology (OR = 7.1, P = 0.016) and in younger cases (p.Lys27Met histone H3.1: 4.11 ± 2.03 years at diagnosis versus wild-type histone H3.1: 6.50 ± 3.50 years at diagnosis; P = 0.040) (Fig. 2c) . TP53 mutations were more likely to occur in cases with GBM histology regardless of p.Lys27Met status (OR = 8.3, P = 0.0039) and were unlikely to occur in cases with
LGA histology (OR = 0.046, P = 0.0040) (Fig. 2c) . A summary of the molecular and clinical features observed among cases in the MYCN, silent and H3-K27M DIPG subgroups is provided in Table 1 .
After H3F3A and TP53, the next most frequently mutated gene in DIPG was ACVR1 (encoding activin A receptor, type I), a new cancer gene. Mutations of ACVR1 in four DIPGs (c.617G>A) resulted in a p.Arg206His substitution (Fig. 3a) . One DIPG had a mutation affecting a neighboring codon (encoding p.Gln207Glu). Two DIPGs had a c.983G>A (p.Gly328Glu) mutation and five DIPGs in our cohort had a c.983G>T mutation that resulted in a p.Gly328Val substitution (Fig. 3a) .
In total, 20% of DIPGs had ACVR1 mutations. ACVR1 encodes the activin A (ALK2) receptor involved in BMP (bone morphogenetic protein) signaling 15 . The p.Arg206His substitution is in the GS (glycineserine-rich) domain and is the most common alteration responsible for an autosomal dominant disease of the connective tissue, fibrodysplasia ossificans progressiva (FOP), in which endothelial cells are sensitized to BMP signaling, transitioning to osteoblasts 15 . The p.Gly328Glu and p.Gln207Glu substitutions are described as rare alterations in individuals with FOP 16, 17 . The p.Gly328Val substitution has not previously been reported in individuals with FOP or in cancer. Mutations affecting the Gly328 residue map to the kinase domain and are spatially close to the GS domain 17 , and, similar to the p.Arg206His substitution, they are thought to weaken the interaction of the GS domain with negative regulators of ACVR1 such as FKBP12, resulting in ligand-independent constitutive activation of the receptor. Levels of phosphorylated SMAD1 and SMAD5 (SMAD1/5) were higher in DIPG cases with ACVR1 mutations compared to cases with wild-type ACVR1 (Fig. 3b) .
To determine the biological consequence of ACVR1 mutations in vitro, we transfected immortalized normal human astrocytes (iNHAs) with 3× Flag-tagged pCDH511b expression vectors containing Gly328Val ACVR1 and/or Lys27Met histone H3.3. Protein blot analysis showed endogenous expression of ACVR1 in all cells, with Flag-ACVR1 and higher total ACVR1 expression detected in transfected cells. To determine whether the ACVR1 mutant activated the BMP signaling pathway, we tested for phosphorylated SMAD1/5 by protein blot. Only cells expressing Gly328Val ACVR1 showed positivity for phosphorylated SMAD1/5 (Fig. 3c) . To test downstream pathway activation, we performed quantitative PCR for ID1 and ID2, which are known targets of BMP signaling [18] [19] [20] . Expression of either a MYCN   Sex   DIPG01  DIPG37  DIPG44  DIPG48  DIPG52  DIPG55  DIPG03  DIPG05  DIPG07  DIPG08  DIPG24  DIPG27  DIPG46  DIPG50  DIPG57  DIPG60  DIPG06  DIPG19  DIPG39  DIPG62  DIPG79  DIPG80  DIPG28  DIPG30  DIPG45  DIPG10  DIPG04  DIPG41  DIPG61  DIPG67  DIPG63  DIPG64  DIPG66  DIPG78  DIPG71  DIPG47  DIPG51  DIPG56  DIPG58  DIPG11  DIPG25  DIPG26  DIPG18  DIPG09  DIPG02  DIPG49  DIPG38 npg l e t t e r s Lys27Met histone H3.3 or Gly328Val ACVR1 alone led to a twofold increase in ID1 and ID2 expression levels, whereas coexpression of these proteins resulted in a nearly fourfold increase in ID1 and ID2 expression levels, suggesting an additive effect (Fig. 3d) . Gly328Val ACVR1 increased the growth rate of iNHAs compared to empty vector controls (P = 0.0034; Fig. 3e ). An increase in the levels of phosphorylated SMAD1/5 was also seen by protein blot in postnatal day (P) 3 mouse brainstem progenitor cells from Nes-tv-a; Tp53 fl mice infected in vitro with RCAS (replication-competent avian sarcoma-leukosis virus long terminal repeat (LTR) with a splice acceptor) expressing Arg206His or Gly328Val mouse ACVR1 compared to wild-type ACVR1 (P < 0.05; data not shown). Brainstem progenitor cells infected with virus expressing mutant ACVR1 showed increased proliferation by BrdU (bromodeoxyuridine) incorporation (P < 0.05; Fig. 3f) .
To assess the impact of Lys27Met histone H3.3 on gene expression and methylation patterns as well as its potential transformative capacity, we transfected iNHA cells with expression vectors encoding N-terminally Flag-tagged wild-type or Lys27Met histone H3.3 or with empty vector control. Clones expressing comparable amounts of wild-type and Lys27Met histone H3.3 protein, according to protein blot analysis (Supplementary Fig. 6a) , that was verified by immunofluorescence staining to localize to the nucleus (Supplementary Fig. 6b ) were selected and pooled to remove clonal variations in phenotype. Compared to controls, iNHA cells expressing Lys27Met histone H3.3 had a significantly reduced proliferation rate when grown adherently in DMEM (P < 0.0001; Supplementary Fig. 6c ) and grew semi-adherently when seeded in neural stem cell (NSC) medium (Supplementary Fig. 6e ). Compared to adherent iNHA cells expressing Lys27Met histone H3.3, the semi-adherent iNHA cells expressing Lys27Met histone H3.3 in NSC medium had higher expression of SOX2 by immunofluorescence staining with no marked changes in GFAP, nestin, TUJ1 or O4 levels (Supplementary Fig. 7 ). Alterations in both the expression (Illumina HT-12v4) and methylation (Illumina Infinium450k) profiles of the cells expressing Lys27Met histone H3.3 compared to both wild-type and empty vector controls were observed (Supplementary Fig. 6f ). The top pathways perturbed by npg l e t t e r s Lys27Met histone H3.3 expression corresponded to molecular and cellular functions, especially an increase in cell-to-cell signaling (P = 0.00882, z score = 2.365) and a decrease in cell cycle progression (P < 0.00001, z score = −1.347). The top molecular and cellular functions affected by methylation changes in cells expressing mutant Lys27Met histone H3.3 were embryonic development (P < 0.00001), decreased cell growth and proliferation (P = 0.00103) and increased cell-to-cell signaling (P < 0.00001). Cells expressing Lys27Met histone H3.3 did not form colonies in soft agar. These cells showed reduced global levels of trimethylation at lysine 27 of histone H3 (H3K27me3) compared to controls (Supplementary Fig. 6d) . Similarly, immunohistochemical staining of DIPGs showed lower global H3K27me3 levels in tumors positive for Lys27Met histone H3.3 compared to tumors with wild-type histone H3.3 ( Supplementary Fig. 6g,h) . Global levels of acetylation at lysine 27 of histone H3 (H3K27ac), trimethylation at lysine 4 of histone H3 (H3K4me3) and acetylation at lysine 9 of histone H3 (H3K9ac) were not altered in a mutationdependent manner (data not shown).
Interestingly, expression of Lys27Met histone H3.3 also led to increased ID1 and ID2 expression yet did not induce phosphorylation of SMAD1/5, suggesting an alternate pathway for its action. Phosphorylated SMAD1/5 was also only observed in DIPG cases with ACVR1 mutations and not in ones expressing the Lys27Met histone H3 mutant that had wild-type ACVR1. Our in vitro data suggest an additive effect of the combination of mutant ACVR1 and H3F3A in increasing ID1 and ID2 levels. Further, a subset of DIPG cases with p.Lys27Met histone H3.3 alterations overexpressed ID2, and MYCN subgroup cases had genomic amplification of ID2 with corresponding increased expression, suggesting a potentially common, ID2-related mechanism in DIPG tumorigenesis. ID2 may have a role in negatively regulating cell differentiation 21 , and its expression has been associated with poor prognosis in other cancers [22] [23] [24] . Morphological changes and differential expression of stem cell markers, as well as global methylation and gene expression changes in iNHA cells expressing Lys27Met histone H3.3, suggest a cellular reprogramming event. However, further investigation into the effects of p.Lys27Met histone H3.3 alteration and ACVR1 mutations in DIPG tumorigenesis is warranted.
Our results highlight the many pathways to tumorigenesis in DIPG. This complexity needs to be considered when designing new therapeutic approaches to improve outcome for affected children.
MeTHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Whole-genome sequencing data are accessible through the European Genome-phenome Archive (accession EGAS00001000575). Methylation data are accessible through the Gene Expression Omnibus (accession GSE50022). Gene expression data are accessible through the Gene Expression Omnibus (accession GSE50021). SNP6.0 copy number data are accessible through the Gene Expression Omnibus (accession GSE50024). 
ONLINe MeTHODS
Patients and samples. Biological material and clinical data were gathered for 74 DIPG samples, including normal brain and/or peripheral blood samples, if available. DIPGs were diagnosed by a neuroradiologist on the basis of magnetic resonance imaging (MRI). A contrasting lesion with diffuse involvement of at least 50% of the pons was required for DIPG diagnosis. All patient material was collected after receiving informed consent and was approved by the institutional review board of contributing centers. Samples for 20 of these patients represented pretreatment samples (2 non-treated patients from autopsy), and 54 samples represented post-treatment autopsy samples. The median age of diagnosis was 6.37 years, with a median survival time of 10.4 months.
Whole-genome sequencing alignment and structural variants. The entire genomes of 20 DIPG tumor and matched normal DNA pairs were sequenced using next-generation Illumina technologies. DNA samples were paired-end sequenced on an Illumina HiSeq 2000 using DNA fragments of 259-333 bp in size with 100-bp read length. Mean coverage was 35-67× for tumor samples and 28-74× for normal samples. The Burrows-Wheeler Aligner (BWA) tool was used to map all reads to GRCh37/hg19 using default parameters 25 . PCR duplicates were removed from alignments using Picard 1.77 (Supplementary Table 6 ). Structural variants were identified using PRISM 1.1.6 and PRISM CTX 1.0. 1 (ref. 26) . Recurrent structural variants (Supplementary Table 7) were found after subtracting common structural variants 27 and all structural variants found in normal tissue and were visually validated using the DNAC algorithm and SNP6.0 data in Partek Genomics Suite (v.6.6) as well as wholegenome sequencing data in Savant (v2.0.3) 28 and the Integrated Genomics Viewer (v2.2). Prediction of structural variants in chromothriptic regions was performed by discordant read-pair clustering. Discordant read pairs (fragment size > 3 × σ + µ) were initially selected by greedy clustering using a sliding window of 15 × σ and were refined by clipped-read mappings, where σ is the s.d. of the insert size and µ is the average insert size ( Supplementary  Fig. 8 ). Localization of a chromothriptic event was predicted using a hidden Markov model (HMM) informed by depth of coverage and discordant read pairs. Maximum-likelihood copy counts of chromothriptic regions were determined as previously described 29 .
Exome capture was carried out with the SOLiD platform (Applied Biosystems). Sequence data were aligned to the GRCh37/hg19 human reference genome assembly; duplicates and reads with non-unique mapping were excluded. We validated 151 sequence variants in 128 genes using PCR amplification by Fluidigm arrays and Ion Torrent chips (Life Technologies). These SNVs were selected for validation on the basis of variant allele frequency from whole-genome sequencing and/or whole-exome sequencing and being found to be significantly altered upon analysis of the combined cohort with MutSig (Broad Institute), an algorithm testing whether the observed mutations in a gene are not simply a consequence of random background mutation processes (Supplementary Table 6 ).
Methylation profiling. Comprehensive methylation profiling of 28 DIPG samples at the Microarray Centre (University Health Network, Toronto, Ontario, Canada) used the Illumina Infinium450k array. Bisulfite conversion was carried out using the EZ DNA Methylation kit (Zymo Research) according to the manufacturer's specifications. Methylation profiling of iNHA cells transfected with vectors expressing Lys27Met and wild-type histone H3.3 was also carried out on this array. DNA was extracted using the DNeasy kit (Qiagen) according to the manufacturer's protocols. Subgrouping and clustering on the basis of differential CpG probe methylation was performed and validated using multiple programs and algorithms, including non-negative matrix factorization (GenePattern, Broad Institute), consensus hierarchical clustering (GenePattern, Broad Institute; ConsensusClusterPlus, Bioconductor/R; MultiExperiment Viewer, Dana-Farber Cancer Institute), k-means clustering (GenePattern, Broad Institute; ConsensusClusterPlus, Bioconductor/R), silhouette clustering (ConsensusClusterPlus, Bioconductor/R) and significance analysis of microarrays (SAM; MultiExperiment Viewer, Dana-Farber Cancer Institute). Subgroups were validated for significance by SigClust (Bioconductor/R).
Gene expression profiling. Expression profiling was conducted on 35 DIPG samples and 10 normal brain controls at the Microarray Centre (University Health Network, Toronto, Ontario, Canada) using the DASL protocol for the Illumina HT-12 V4 BeadChip array. Differential gene expression in iNHA cells transfected with vector expressing Lys27Met or wild-type histone H3.3 was also assessed on this array. RNA was extracted using the QIAShredder and RNeasy kit (Qiagen) according to the manufacturer's specifications. RNA quality was assessed using the Bioanalyzer 2100 (Agilent Technologies). RNA Integrity Number (RIN) ranged from 1.3 to 8.2. Microarray data were normalized in Partek Genomics Suite v6.6 using per-probe median-centered quantile normalization. Data analysis was conducted on log 2 -transformed data or fold change data (relative to non-neoplastic brain). Genes differentially expressed among the subgroups were identified using one-way ANOVA, and significance was corrected for false discovery rate.
Copy number analysis. Copy number analysis was conducted for 40 DIPG samples using SNP6.0 (Affymetrix). Digestion, labeling and hybridization of DNA were performed by the Centre for Applied Genomics at The Hospital for Sick Children or at the Microarray Centre at the University Health Network. CEL data were analyzed for CNAs using the segmentation tool and HMM in Partek Genomics Suite v6.6 and Genotyping Console 4.1 (GTC4.1; Affymetrix) as previously described 9 .
In vitro modeling of Lys27Met histone H3.3 and Gly328Val ACVR1. iNHA cells 30 were grown in DMEM supplemented with 10% FBS (Invitrogen). Cells were tested and found to be negative for mycoplasma. Cells were passaged at 80% confluence. Clones expressing wild-type and mutant (Lys27Met) histone H3.3 (H3F3A) were created by site-direction mutagenesis and PCR using pCMV SPORT6 plasmid (Addgene) containing mouse H3f3a cDNA. Expression of Flag-tagged wild-type and Lys27Met H3F3A was established by cloning the corresponding cDNAs into p3xFLAG-CMV-10 vectors (SigmaAldrich) (see Supplementary Table 8 for primer sequences). Clones were confirmed by bidirectional Sanger sequencing. Cells were transfected using FuGENE 6 transfection reagent (Promega) according to the manufacturer's instructions.
To generate stable transfectants, iNHA cells were cotransfected with a DNA fragment containing the hygromycin gene. Stably transfected clones were selected with 300 µg/ml hygromycin and were pooled to eliminate clonal variations in phenotype. For the isolation of DNA and RNA used for expression and methylation arrays, respectively, cells were collected at passages 4 and 15 at about 80% confluence. Total cell pellet for each sample was divided into two parts, one used for the isolation of genomic DNA and the other used for the isolation of RNA. Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen), and bisulfite conversion was carried out using the EZ DNA Methylation kit. Total RNA was isolated by RNeasy kit. iNHA cells from passages 4 and 15 were analyzed on methylation (Infinium 450k) and expression (Illumina HT-12 v4) arrays by similar methods to those described for patient samples.
ACVR1 mutants were created from human ACVR1 cDNA using the QuikChange Site-Directed Mutagenesis kit (Stratagene) (see Supplementary  Table 8 for primer sequences). The c.983G>T mutation was generated resulting in the p.Gly328Val amino acid change. The sequence encoding the Gly328Val ACVR1 mutant was then subcloned into the pCDH511b vector (System Biosciences) in frame with sequence for 3× Flag tag at the 3′ end of the cDNA with pCDH511b, pCDH511b-Gly328Val-ACVR1, pCDH511b-Lys27Met-H3.3 or pCDH511b-Gly328Val-ACVR1 and pCDH511b-Lys27Met-H3.3. Cells were harvested 72 h after transfection, and protein and RNA were extracted for protein blot and quantitative PCR analyses, respectively. Protein blotting was conducted using antibodies to phosphorylated SMAD1/5 (1:1,000 dilution; Cell Signaling Technology, 9516), total SMAD1 (1:1,000 dilution; Cell Signaling Technology, 6944), Flag (1:1,000 dilution; Sigma, F3165) and ACVR1 (1:1,000 dilution; Cell Signaling Technology, 4398). Reverse transcription was conducted using the RevertAid First-Strand cDNA Synthesis kit (Thermo Scientific). See Supplementary Table 8 for RT-PCR primer pairs.
Cell counting and cell proliferation. Cell counting on iNHA cells expressing Lys27Met histone H3.3 and Gly328Val ACVR1 as well as control iNHA cells was performed in triplicate using the automated Vi-Cell Viability Analyzer from Beckman-Coulter. Cell proliferation was measured by BrdU npg
